Neurological Soft Signs in Schizophrenia: A Meta-analysis by Chan, Raymond C. K. et al.
Neurological Soft Signs in Schizophrenia: A Meta-analysis
Raymond C. K. Chan1–3, Ting Xu2,4,5,
R. Walter Heinrichs6, Yue Yu2,7, and Ya Wang2,3
2Neuropsychology and Applied Cognitive Neurosciences Labora-
tory, Institute of Psychology; 3Key Laboratory of Mental Health,
Institute of Psychology; 4Graduate School, Chinese Academy of
Sciences, Beijing, China; 5School of Information, Renmin Uni-
versity of China, Beijing, China; 6Department of Psychology, York
University, Toronto, Canada; 7Department of Psychology and
Yuanpei College, Peking University, Beijing, China
Background: Neurological soft signs (NSS) are hypothe-
sized as candidate endophenotypes for schizophrenia, but
their prevalence and relations with clinical and demographic
data are unknown. The authors undertook a quantification
(meta-analysis) of the published literature on NSS in
patients with schizophrenia and healthy controls. A system-
atic search was conducted for published articles reporting
NSS and related data using standard measures in schizo-
phrenia and healthy comparison groups.Method: A system-
atic search was conducted for published articles reporting
data on the prevalence of NSS in schizophrenia using stan-
dard clinical rating scales and healthy comparison groups.
Meta-analyses were performed using the Comprehensive
Meta-analysis software package. Effect sizes (Cohen d)
indexing the difference between schizophrenic patients and
the healthy controls were calculated on the basis of reported
statistics. Potential moderator variables evaluated included
age of patient samples, level of education, sample sex pro-
portions, medication doses, and negative and positive symp-
toms.Results: A total of 33 articles met inclusion criteria for
the meta-analysis. A large and reliable group difference
(Cohen d) indicated that, on average, a majority of patients
(73%) perform outside the range of healthy subjects on ag-
gregate NSS measures. Cognitive performance and positive
and negative symptoms share 2%–10%of their variance with
NSS. Conclusions: NSS occur in a majority of the schizo-
phrenia patient population and are largely distinct from
symptomatic and cognitive features of the illness.
Key words: neurological soft signs/meta-analysis/
schizophrenia
Introduction
Schizophrenia is a loose and complex neuropsychiatric
syndrome characterized by a range of cognitive1 and psy-
chophysiological deficits.2 Beginning with the seminal re-
view by Heinrichs and Buchanan,3 the study of
neurological soft signs (NSS) has provided an additional
and increasingly important perspective on the illness.
Conventionally defined as nonlocalizing abnormalities
without diagnostic specificity, NSS involve observable
defects in sensory integration (SI), motor coordination
(MC), and inhibition. Tsuang and colleagues4,5 have ar-
gued that these defects reflect genetic and nongenetic
processes underpinning the predisposition to psychotic
illness. Moreover, the assumption of nonfocal neural rep-
resentation is being revised in light of evidence that NSS
have identifiable cerebral correlates.6–8 Current views
consider these signs as covariates of attention,9–13 verbal
ability,14,15 and visual-spatial memory.10,16,17 It follows
that NSS and cognitive findings have emerged as candi-
date endophenotypes for schizophrenia-spectrum
disorders.18,19
Evaluating the strength of evidence in support of NSS
as key indicators of psychotic illness has been compli-
cated by a number of potentially confounding variables
including duration of illness, medication doses, and the
use of different measurement techniques. Although sys-
tematic reviews addressing the issues of NSS in schizo-
phrenia have appeared in the past decades, all were
narrative reviews (eg, Bombin et al,18 Heinrichs and
Buchanan,3 Bombin et al20). Although valuable, narra-
tive reviews do not quantify the strength or consistency
of evidence in a field or test hypotheses about moderators
underlying the variability between study findings. Meta-
analytic techniques of research synthesis provide the
most objective way of assessing the magnitude and con-
sistency of differences between people with and without
schizophrenia.21,22 Research synthesis aggregates data on
the same or highly similar dependent measures from mul-
tiple independent studies, expresses differences between
schizophrenia patients and healthy comparison subjects
in pooled SD units (ie, the effect size), and yields CIs for
mean effect sizes.23
Recent meta-analyses suggest that deficits in cogni-
tive measures consistently distinguish a majority of
schizophrenia patients from healthy, nonpsychiatric
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subjects.21,24,25 However, little is known about the rela-
tive prevalence of NSS in schizophrenia patients and
healthy samples. In addition, there are a few published
estimates of the strength of association between soft
signs, symptoms, and neurocognitive functions in the
schizophrenia population. Moreover, the relative preva-
lence of NSS in relatives of schizophrenia patients
remains unknown in terms of quantification and consis-
tency across the research literature. Thus, although NSS
are regarded as candidate endophenotypes for schizo-
phrenia, it is not clear whether data obtained from rela-
tives parallel the deficits found in patients.
In light of these considerations, we undertook a meta-
analysis to address a number of issues concerning the
magnitude, consistency, and mediation of NSS in schizo-
phrenia. First, we aimed to determine the average stan-
dardized difference in NSS between patients with
schizophrenia and healthy research participants. Second,
we were interested in estimating the average magnitude
of association between NSS, psychiatric symptoms, and
neurocognitive functions in the schizophrenia population.
Third, we sought to evaluate potential moderator varia-
bles that may contribute to differences between patients
and healthy participants. These moderators included
patients’ ages, level of education, sex, medication, and neg-
ative and positive symptom severity.
Methods
Potential articles were identified through a comprehen-
sive search using literature databases of Elsevier Science,
EBSCOHost (PsychINFO, PsychARTICLE), and Med-
Line between 1966 and January 2008. The key words
were ‘‘neurological soft signs,’’ ‘‘neurological signs,’’
‘‘soft signs,’’ ‘‘neurological abnormalit*,’’ ‘‘motor coor-
dination,’’ ‘‘sensory integration,’’ ‘‘disinhibition,’’ ‘‘com-
plex motor sequencing,’’ ‘‘Luria task,’’ ‘‘fist-edge-palm,’’
‘‘schizophrenia,’’ ‘‘schizotypal,’’ and ‘‘schizotypy.’’ Ad-
ditional articles were obtained from the reference lists
of the initial article base and from a search from January
2007 through January 2008 of journals that frequently
published articles on NSS in schizophrenia. This strategy
was used to minimize the possibility of overlooking very
recent articles not included in computerized databases.
These journals included Acta Psychiatrica Scandinavica,
American Journal of Psychiatry, Archives of General
Psychiatry, British Journal of Psychiatry, Journal of Ab-
normal Psychology, European Archives of Psychiatry and
Clinical Neuroscience, Journal of Nervous andMental Dis-
eases, Neuropsychology, Neuropsychologia, Psychiatry
Research, Psychological Medicine, Schizophrenia Bulle-
tin, and Schizophrenia Research. These search procedures
yielded an initial pool of 172 potential articles for inclu-
sion.
The following criteria were used to select studies in the
initial pool for quantitative analysis. Each study required
at least one of the criteria: (1) patients and controls’
scores means or t value obtained from NSS instruments
such as the Neurological Evaluation Scale (NES)26 and
the Cambridge Neurological Inventory (CNI)27; (2) the
correlation coefficient between NSS and psychiatric
symptom ratings from instruments including the Brief
Psychiatric Rating Scale (BPRS),28 Positive and Negative
Syndrome Scale (PANSS),29 the Scale for Assessment of
Positive Symptoms,30 and the Scale for Assessment of
Negative Symptoms31; and (3) the correlation coefficient
between NSS and scores of neurocognitive performance
from standard tests such as the Wechsler Adult Intelli-
gence Scale,32,33 Trail Making Test,34 and Wisconsin
Card Sorting Test,35 etc.
This procedure yielded a study base of 57 published
reports, with 40 contrasting NSS (included total and sub-
scale) schizophrenic and healthy control samples, 14
reporting correlation coefficients between NSS and neu-
rocognitive scores, and 18 reports of correlation coeffi-
cients between NSS and symptom scores.
We recorded potential moderator variables including
(1) the name of the first author, year of publication,
and the order for sorting; (2) schizophrenia diagnostic
criteria used (Diagnostic and Statistical Manual ofMental
Disorders [Third Edition], Diagnostic and Statistical
Manual of Mental Disorders [Third Edition Revised],
or Diagnostic and Statistical Manual of Mental Disorders
[Fourth Edition]; International Classification of Diseases,
Ninth Revision or Tenth Revision); (3) descriptions of
basic information including sample size, gender, age, ed-
ucation, age on set, duration of illness, chronic vs first-
episode schizophrenia; (4) NSS scale (ie, NES, CNI, Con-
densed Neurological Examination,36 etc) and NSS score
of patients and controls (mean, SD, t value, P value); (5)
correlation coefficient comparing patients’ NSS scores
with their symptoms scores; and (6) correlation coeffi-
cient comparing patients’ NSS scores with their neuro-
cognitive function test score.
Data Analysis
All analyses were performed using the Comprehensive
Meta-analysis (CMA) software package.37 Effect sizes
(Cohen d) indexing the difference between schizophrenia
patients and the healthy controls were calculated on the
basis of reported statistics (mean of schizophrenia sample
minus the mean of the healthy control group, divided by
the pooled SD). When means and SDs were not available,
effect size d was computed from t or F values or estimated
from exact P values. Standard meta-analytic methods
were adopted to obtain mean effect sizes weighted for
study variance and averaged across primary studies.23
Stability of the mean effect was estimated by its 95%
CI. In addition, the homogeneity statistic, Q, was calcu-
lated to test whether individual study effect sizes for any
given variable likely reflect a single common population
effect size. A significant Q statistic indicates heterogeneity
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of the individual study effect sizes, implying multiple un-
derlying effect populations and the need to analyze po-
tential moderators of effect size variability.23
Due to the existence of the hypothetical ‘‘file-drawer
problem,’’38 whereby mean effect sizes based on published
findings may be overturned by the existence of discrepant
unpublished findings,39 it is recommended that researchers
use estimation procedures to assess the likelihood of this
possibility. Thus, a fail-safe number estimates the number
of unpublished studies with nil or minimal effect sizes re-
quired to reduce an overall effect size to some specified
negligible value.38,40 We set this negligible level at 0.2
and assumed a value of 0.1 for hypothetically ‘‘missing’’
or unpublished studies. A second method is a 2-step ap-
proach that uses both visual inspection of graphic data
and estimation procedures. First, individual study effect
sizes are plotted against their SEs, giving rise to a ‘‘funnel’’
shape or distribution in the ideal situation and suggesting
the absence of bias. On the other hand, skewing and asym-
metry in the effect distribution imply a publication bias.41
Duval and Tweedie42 developed a method whereby ‘‘miss-
ing’’ study effects that correct the hypothetical bias and
graphic asymmetry are estimated and included along
with the published studies to yield an adjusted mean effect
size. This procedure was carried out with the CMA soft-
ware. Finally, moderator variables evaluated in relation to
both uncorrected and corrected effect sizes included age of
patient samples, level of education, sample sex propor-
tions, medication doses, and negative and positive symp-
toms.
Results
The primary study base yielded 34 schizophrenia-control
comparisons of NSS total score data drawn from 33 in-
dependent studies. One study43 was excluded because it
reported the same data as Ismail et al,44 which was in-
cluded in the study base. All these comparisons were
reported as being statistically significant in the original
studies. Grand mean effect sizes for total and selective
NSS scores along with their 95% CIs and homogeneity
statistics are presented in table 1. The aggregated NSS
















Contrasting NSS total score 33 2345 1984 1.591 0.109 (1.377, 1.805) 277.093* 341
NSS measured by NES or
modified NES
22 1382 1229 1.554 0.137 (1.285, 1.822) 170.285* 219
NSS measured by CNI 5 688 553 1.404 0.275 (0.866, 1.943) 65.172* 47
First-episode schizophrenia only 9 646 717 1.526 0.238 (1.060, 1.992) 97.806* 74
Chronic/mixed 24 1699 1267 1.613 0.120 (1.378, 1.848) 160.826* 272
Contrasting NSS-MC score 24 1926 1510 0.977 0.094 (0.793, 1.161) 128.686* 175
NSS measured by NES or
modified NES
14 990 742 0.878 0.088 (0.705, 1.051) 31.253 93
NSS measured by CNI 8 871 728 1.110 0.211 (0.697, 1.523) 93.596* 64
First-episode schizophrenia only 7 661 610 0.968 0.140 (0.693, 1.242) 26.016* 51
Chronic/mixed 17 1265 900 0.979 0.126 (0.731, 1.226) 102.661* 125
Contrasting NSS-SI score 23 1839 1456 0.823 0.087 (0.652, 0.994) 104.487* 106
NSS measured by NES or
modified NES
15 1022 774 0.872 0.122 (0.633, 1.111) 68.838* 65
NSS measured by CNI 7 778 660 0.739 0.140 (0.464, 1.014) 33.144* 34
First-episode schizophrenia only 7 600 574 0.754 0.170 (0.421, 1.086) 35.659* 22
Chronic/mixed 16 1239 882 0.854 0.100 (0.659, 1.049) 58.989* 88
Contrasting NSS-MSeq (NES)
score
15 1001 721 0.795 0.127 (0.546, 1.044) 71.407* 62
First-episode schizophrenia only 6 482 414 0.677 0.204 (0.276, 1.078) 31.001* 16
Chronic/mixed 9 519 307 0.874 0.156 (0.569, 1.179) 30.220* 54
Contrasting NSS-disinhib
(CNI) score
8 909 711 0.970 0.180 (0.617, 1.322) 69.388* 56
Note: NSS = neurological soft signs; Std Diff = standard difference in means; NES = Neurological Evaluation Scale; CNI = Cambridge
Neurological Inventory; MC = motor coordination; SI = sensory integration; MSeq = complex motor sequencing; disinhib =
disinhibition.
*Q value heterogeneous, P < .05.
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total score mean effect was large, corresponding to 73%
separation of joint schizophrenia and control distribu-
tions.45 However, the individual effects were not homo-
geneous as indexed by the Q statistic. Moreover, the
funnel plot (figure 1) showed a higher concentration of
studies on the right side of the mean, suggesting a bias
against publishing small studies with no effect. Therefore,
the CMA recomputed the effect size using the method of
Duval and Tweedie40 described previously. The number
of ‘‘missing’’ studies and adjusted effect size and adjusted
Q statistic are shown in table 2. The adjusted standard
difference in means is lower than uncorrected results
for NSS total and for every subscale comparison. Never-
theless, the fail-safe number of studies required to over-
turn the mean effect size was 341, which is sufficiently
large to make the existence of large numbers of unpub-
lished negligible findings unlikely. Analysis of data de-
rived from first-episode schizophrenia and chronic
patient samples also revealed large mean effect sizes
that were statistically indistinguishable. Similarly, there
was no evidence for greater sensitivity of type of NSS in-
strument (ie, NES vs CNI). However, mean d‘s and as-
sociated CIs show that NSS indexed by a total score,
rather than subscales indexing sensory and motor items,
provides the most sensitive discrimination of patients and
controls. Mean effect sizes for all subscale scores were less
than d = 1.0. At the same time, all quantified literatures
with the exception of studies reporting MC subscale
scores based on the NES revealed significant heterogene-
ity as indexed by Q tests (figures 1–4).
Pearson correlation coefficients between NSS total and
subscale scores and aggregated and selective neurocogni-
tive test scores are presented in tables 3 and 4. Several
literatures were represented by small numbers of primary
studies.11,13,15,17,46–50 However, it is noteworthy that NSS





(Adjusted 95% CI) Adjusted Q Value
Contrasting NSS total score 14 1.077 (0.844, 1.310) 561.558*
NSS measured by NES or modified NES 9 1.041 (0.751, 1.331) 342.637*
NSS measured by CNI 2 0.950 (0.339, 1.561) 144.857*
First-episode schizophrenia only 4 0.848 (0.340, 1.357) 205.437*
Chronic/mixed 10 1.176 (0.918, 1.433) 332.353*
Contrasting NSS-MC score 8 0.726 (0.512, 0.941) 308.755*
NSS measured by NES or modified NES 3 0.749 (0.550, 0.948) 62.317*
NSS measured by CNI 2 0.838 (0.381, 1.295) 175.308*
First-episode schizophrenia only 3 0.757 (0.447, 1.066) 66.126*
Chronic/mixed 0 — —
Contrasting NSS-SI score 11 0.516 (0.332, 0.700) 232.101*
NSS measured by NES or modified NES 7 0.517 (0.267, 0.768) 139.946*
NSS measured by CNI 0 — —
First-episode schizophrenia only 3 0.432 (0.085, 0.780) 67.380*
Chronic/mixed 2 0.755 (0.539, 0.971) 82.997*
Contrasting NSS-Mseq (NES) score 7 0.389 (0.116, 0.663) 183.344*
First-episode schizophrenia only 3 0.234 (0.196, 0.664) 86.628*
Chronic/mixed 1 0.777 (0.440, 1.113) 41.204*
Contrasting NSS-disinhib (CNI) score 2 0.710 (0.287, 1.132) 169.308*
Note: NSS = neurological soft signs; Std Diff = standard difference in means; NES = Neurological Evaluation Scale; CNI = Cambridge
Neurological Inventory; MC = motor coordination; SI = sensory integration; MSeq = complex motor sequencing; disinhib =
disinhibition.
*Q value heterogeneous, P < .05.
Fig. 1. Funnel Plot for the Meta-analysis of Differences in
Neurological Soft Signs Total Scores Between Schizophrenia
Patients and Healthy Controls.
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total, MC, and SI associate significantly with cognitive
performance collapsed across tasks. In addition, with
10 primary studies reporting data from executive func-
tion tasks, the relationship between cognition and NSS
total scores is similar in magnitude to the collapsed find-
ings. Correlations between NSS scales and symptom se-
verity (PANSS, BPRS) are presented in tables 5 and 6.
Significant relationships were found between NSS total
and both total and negative symptoms, with shared var-
iances of 10%–12%. In contrast, while CIs for the mean
value for NSS total and positive symptoms excluded 0,
the effect size was relatively modest with less than 4%
shared variance (figures 5 and 6).
Moderator Variables
Heterogeneity statistics reported in tables 1–6 revealed
the presence of significant effect variability in many of
the NSS literatures in the study base. Accordingly, it
was of interest to assess moderator variables that may
vary with effect magnitudes in these literatures. We exam-
ined the effect of several potential moderator variables,
including mean age of patient samples, duration of ill-
ness, and education. Sample sex proportions, medication
status, and symptom severity could not be considered as
moderators due to inadequate reporting of relevant data
in the primary studies (table 7).
In our analysis, age was a significant moderator of the
NSS total score contrast between schizophrenia and con-
trol groups, whereby study effect sizes decreased as mean
ages of patient samples increased. However, age was not
a significant moderator when only NES data were ana-
lyzed. Age also moderated the complex motor sequencing
(MSeq) but not MC and SI scores contrasting schizo-
phrenic patients and controls. Moreover, age was not
a significant moderator for any correlation coefficient
Fig. 2. Funnel Plot for the Meta-analysis of Differences in
Neurological Soft Signs Motor Coordination Scores Between
Schizophrenia Patients and Healthy Controls.
Fig. 4. Funnel Plot for the Meta-analysis of Differences in
Neurological Soft Signs Complex Motor Sequencing Scores
Between Schizophrenia Patients and Healthy Controls.
Fig. 3. Funnel Plot for the Meta-analysis of Differences in
Neurological Soft Signs Sensory Integration Scores Between
Schizophrenia Patients and Healthy Controls.
Fig. 5. Funnel Plot for the Meta-analysis of Correlation Between
NSS Total Scores and Neurocognitive Test Scores in Schizophrenia
Patients.
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(95% CI) Q Value
Correlation between NSS total score
and cognitive abilities
48 3789 0.331 (0.362, 0.299) 54.972
NSS-MC subscale 24 1816 0.332 (0.378, 0.283) 28.199
NSS-SI subscale 31 2435 0.374 (0.409, 0.339) 30.589
NSS-Mseq subscale 6 489 0.313 (0.392, 0.23) 3.253
NSS-disinhib subscale 17 1653 0.177 (0.251, 0.101) 37.535*
Correlation between NSS total score
and verbal memory
4 383 0.305 (0.394, 0.21) 0.955
(WMS-R verbal pairs; paired associate learning; logical memory—immediate, delayed; CVLT)
NSS-MC subscale 5 423 0.296 (0.397, 0.182) 5.71
NSS-SI subscale 6 508 0.354 (0.429, 0.274) 2.687
NSS-disinhib subscale 4 338 0.058 (0.166, 0.05) 2.037
Correlation between NSS total score and
nonverbal memory
6 608 0.374 (0.485, 0.252) 13.851*
(WMS-R visual reproduction—immediate, delayed; visual pairs; ROCFT)
NSS-MC subscale 4 338 0.396 (0.483, 0.3) 1.942
NSS-SI subscale 7 554 0.417 (0.485, 0.345) 1.748
NSS-Mseq subscale 1 85 0.3 (0.482, 0.093) NA
NSS-disinhib subscale 4 338 0.117 (0.241, 0.009) 3.95
Correlation between NSS total score
and motor
4 360 0.299 (0.392, 0.291) 0.363
(Finger tapping test, Purdue pegboard task)
Correlation between NSS total
score and attention
8 579 0.292 (0.382, 0.197) 9.892
(TMT-A, B time; WAIS-R—digit span; reading span test; Stroop; Continuous Performance Test; SART)
NSS-MC subscale 2 82 0.274 (0.6, 0.13) 3.147
NSS-SI subscale 4 252 0.282 (0.393, 0.161) 2.058
NSS-Mseq subscale 1 85 0.26 (0.448, 0.05) NA
NSS-disinhib subscale 1 51 0.015 (0.289, 0.262) NA
Correlation between NSS total
score and IQ
6 580 0.336 (0.443, 0.218) 10.952
(WAIS-R—full scale, verbal, performance; WAIT-III; MWT-B, Ammons Quick Test)
NSS-MC subscale 4 353 0.26 (0.474, 0.017) 12.788*
NSS-SI subscale 5 456 0.468 (0.541, 0.388) 4.306
NSS-Mseq subscale 1 79 0.18 (0.386, 0.043) NA
NSS-disinhib subscale 2 246 0.35 (0.456, 0.234) 0
Correlation between NSS total
score and spatial ability
5 233 0.268 (0.386, 0.141) 1.958
(WAIS-R block design, picture arrangement, picture completion)
NSS-MC subscale 2 62 0.355 (0.109, 0.56) 0.017
NSS-SI subscale 1 85 0.36 (0.532, 0.159) 0
Correlation between NSS total
score and executive function
10 641 0.361 (0.428, 0.29) 8.974
(WCST categories achieved, preservative errors, total errors)
NSS-MC subscale 6 440 0.335 (0.417, 0.248) 1.427
NSS-SI subscale 4 246 0.209 (0.328, 0.084) 0.486
NSS-Mseq subscale 3 240 0.377 (0.482, 0.261) 0.213
NSS-disinhib subscale 4 431 0.289 (0.141, 0.424) 7.445
Correlation between NSS total score
and language function
4 344 0.354 (0.257, 0.445) 2.597
(WAIS-R vocabulary, WRAT-vocabulary, VF)
NSS-MC subscale 1 118 0.374 (0.52, 0.207) NA
NSS-SI subscale 4 334 0.384 (0.473, 0.288) 1.748
NSS-disinhib subscale 1 118 0.147 (0.204, 0.089) NA
Note: NSS = neurological soft signs; MC = motor coordination; SI = sensory integration; MSeq = complex motor sequencing; disinhib =
disinhibition; WMS-R = Wechsler Memory Scale-Revised; CVLT = California Verbal Learning Test; ROCFT = Rey Auditory Verbal
Learning Test; NA, not available; TMT-A, B=Trail-Making Test—A, B; WAIS-R=Wechsler Adult Intelligence Scale-Revised; WAIT-III=
Wechsler Adult Intelligence Test-III; SART= Sustained Attention to Response Test; MWT-B=Mehrfachwahl-Wortschatz-Intelligenz Test;
WCST = Wisconsin Card Sorting Test; WRAT = Wide Range Achievement Test; VF = verbal fluency from Controlled Word Association
Test; NA = Not Available.
*Q value heterogeneous, P < .05.
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Correlation between NSS total
score and cognitive abilities
47 0 — —
NSS-MC subscale 24 0 — —
NSS-SI subscale 31 0 — —
NSS-Mseq subscale 6 0 — —
NSS-disinhib subscale 17 0 — —
Correlation between NSS total
score and verbal memory
4 0 (right side 2) — —
(WMS-R verbal pairs; paired associate learning; logical memory—immediate, delayed; CVLT)
NSS-MC subscale 5 0 — —
NSS-SI subscale 6 2 0.325 (0.394, 0.253) 5.248
NSS-disinhib subscale 4 0 (right side 1)
Correlation between NSS total
score and nonverbal memory
6 1 0.344 (0.455, 0.221) 18.183
(WMS-R visual reproduction—immediate, delayed; visual pairs; ROCFT)
NSS-MC subscale 4 0 — —
NSS-SI subscale 7 0 — —
NSS-Mseq subscale 1 NA — —
NSS-disinhib subscale 4 2 0.056 (0.187, 0.078) 9.192
Correlation between NSS total
score and motor
4 1 0.29 (0.378, 0.197) 0.673
(Finger tapping test, Purdue pegboard task)
Correlation between NSS total
score and attention
8 0 — —
(TMT-A, B time; WAIS-R—digit span; reading span test; Stroop; Continuous Performance Test; SART)
NSS-MC subscale 2 NA — —
NSS-SI subscale 4 0 — —
NSS-Mseq subscale 1 NA — —
NSS-disinhib subscale 1 NA — —
Correlation between NSS total
score and IQ
6 0 (right side 2) — —
(WAIS-R—full scale, verbal, performance; WAIT-III; MWT-B; Ammons Quick Test)
NSS-MC subscale 4 0 (right side 2) — —
NSS-SI subscale 5 1 0.451 (0.529, 0.367) 6.142
NSS-Mseq subscale 1 NA — —
NSS-disinhib subscale 2 NA — —
Correlation between NSS total
score and spatial ability
5 0 — —
(WAIS-R block design, picture arrangement, picture completion)
NSS-MC subscale 2 NA — —
NSS-SI subscale 1 NA — —
Correlation between NSS total
score and executive function
10 2 0.341 (0.412, 0.266) 12.746
(WCST categories achieved; preservative errors; total errors; SET)
NSS-MC subscale 6 2 0.316 (0.391, 0.237) 2.937
NSS-SI subscale 4 0 (right side 2) — —
NSS-Mseq subscale 3 NA — —
NSS-disinhib subscale 4 NA — —
Correlation between NSS total
score and language function
4 1 0.329 (0.412, 0.240) 3.946
(WAIS-R vocabulary; WRAT-vocabulary; VF)
NSS-MC subscale 1 NA — —
NSS-SI subscale 4 1 0.371 (0.456, 0.279) 2.461
NSS-disinhib subscale 1 NA — —
Note: NSS = neurological soft signs; MC = motor coordination; SI = sensory integration; MSeq = complex motor sequencing; disinhib =
disinhibition; WMS-R = Wechsler Memory Scale-Revised; CVLT = California Verbal Learning Test; ROCFT = Rey Auditory Verbal
Learning Test; NA, not available; TMT-A, B = Trail-Making Test—A, B; WAIS-R = Wechsler Adult Intelligence Scale-Revised;
SART = Sustained Attention to Response Test; WAIT-III = Wechsler Adult Intelligence Test-III; MWT-B = Mehrfachwahl-
Wortschatz-Intelligenz Test; WCST = Wisconsin Card Sorting Test; SET = Six-Elements Test; WRAT = Wide Range Achievement
Test; VF = verbal fluency from Controlled Word Association Test; NA = Not Available.
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between NSS total and symptoms. In addition, the cor-
relation coefficients between NSS total and IQ increased
with the mean age of patient samples.
On the other hand, duration of illness was a significant
moderator of the NSS total effect between schizophrenia
and control groups. Duration of illness was also a signif-
icant moderator for the correlation coefficient between
NSS total and IQ. However, duration of illness was
not a significant moderator of the correlation between
NSS total and symptoms. Finally, education did not
moderate any NSS total score contrast between schizo-
phrenia and control samples and was not a significant
moderator of correlations between NSS and symptom se-
verity or neurocognitive performance.
In the current study, we would also like to explore the
handedness and treatment effect as moderator previ-
ously, but many studies reported results without concrete
data. Besides, different methods varied across these stud-
ies.
There were only 7 studies concerning the association of
handedness and soft signs, but 3 of them51–53 reported no
significant correlations between handedness and NSS; 3
Table 5. Results of Meta-analyses of Correlations of NSS and Clinical Symptoms in Schizophrenia Patients
Number of Studies
Number of
Schizophrenic Patients Corr (95%CI) Q Value
Correlation between NSS total score
and symptom total score
11 696 0.327 (0.213, 0.432) 23.341*
NSS-MC subscale 7 516 0.293 (0.142, 0.430) 18.262*
NSS-SI subscale 7 537 0.237 (0.154, 0.316) 5.323*
NSS-Mseq subscale 7 515 0.216 (0.107, 0.319) 9.171
Correlation between NSS total score
and symptom-positive score
10 529 0.192 (0.067, 0.312) 16.578
NSS-MC subscale 6 434 0.153 (0.003, 0.296) 11.493*
NSS-SI subscale 6 434 0.143 (0.028, 0.306) 14.854*
NSS-Mseq subscale 6 394 0.095 (0.017, 0.205) 5.989
Correlation between NSS total score
and symptom-negative score
15 758 0.346 (0.260, 0.426) 20.728
NSS-MC subscale 7 484 0.252 (0.140, 0.357) 9.183
NSS-SI subscale 6 434 0.194 (0.100, 0.284) 1.627
NSS-Mseq subscale 8 467 0.217 (0.099, 0.330) 11.122
Note: NSS = neurological soft signs; MC = motor coordination; SI = sensory integration; MSeq = complex motor sequencing; Corr =
Correlation coefficient.
*Q value heterogeneous, P < .05.






Q Value Fail-Safe N
Correlation between NSS total score
and symptom total score
0 — — 14
NSS-MC subscale 2 0.224 (0.071, 0.367) 28.755* 6
NSS-SI subscale 2 0.206 (0.125, 0.285) 8.762* 3
NSS-Mseq subscale 2 0.156 (0.030, 0.276) 18.682* 1
Correlation between NSS total score
and symptom-positive score
2 0.155 (0.032, 0.273) 20.538 —
NSS-MC subscale 2 0.086 (0.068, 0.236) 18.769* NS
NSS-SI subscale 2 0.034 (0.151, 0.217) 30.806* NS
NSS-Mseq subscale 1 0.077 (0.035, 0.187) 7.52 NS
Correlation between NSS total score
and symptom-negative score
5 0.296 (0.205, 0.382) 33.183 22
NSS-MC subscale 0 — — 4
NSS-SI subscale 0 — — —
NSS-Mseq subscale 2 0.177 (0.062, 0.287) 15.376 2
Note: NSS = neurological soft signs; Std Diff = standard difference in means; MC = motor coordination; SI = sensory integration; MSeq =
complex motor sequencing; NS, not significant.
*Q value heterogeneous, P < .05.
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studies55–57 indicated that there were significant differen-
ces between mixed-handed and hand-preference patients.
One study57 presented a trend for an association between
left-handedness and NSS. Among these studies, 2 stud-
ies51,52 did not report data, while others used different
methods (correlation coefficient or t test) resulting in in-
sufficient data for us to compute the effect size of hand-
edness on soft signs.
Although there were 30 studies (see table 8) that men-
tioned the relationship between treatment and NSS,
many of them did not mention actual descriptive data
or useable data for computation. Among these 30 studies,
only 5 studies reported the relevant results. Therefore, we
cannot calculate the effect size moderated by treatment.
Besides, the majority of studies demonstrated nonsignif-
icant results suggesting that treatment might not be a sig-
nificant moderator.
In addition, only 2 studies79,80 compared the typical and
atypical antipsychotics effect on NSS and found nonsignif-
icant difference.
There were very limited studies on the issue of comor-
bidity on NSS. In the literature, only one study compared
the schizophrenia with and without obsessive-compulsive
disorder (OCD). The authors indicated that OCD-
schizophrenic patients had higher scores on total-NSS
than non–OCD-schizophrenic group. Therefore, it is dif-
ficult to calculate and combine the results in the current
meta-analysis.
Discussion
Our meta-analytic review of NSS in schizophrenia sug-
gests that the illness expresses itself strongly in these basic
motor and sensory deficiencies, with mean effects similar
or larger in magnitude than those reported in neurobeha-
vioral and neurobiological literatures.19,81 The most ro-
bust findings were obtained with a summary index of
NSS. In addition, we found evidence of associations be-
tween NSS and both cognitive performance and negative
symptoms. Moreover, effect sizes were significantly mod-
erated by age and duration of illness. Therefore, the sub-
stantial difference between schizophrenia patients and
controls suggests that NSS meet one essential criterion
(association with illness) of an endophenotype for schizo-
phrenia.
Contrast of NSS Between Schizophrenia Patients and
Healthy Controls
Our findings show a large and reliable effect indicating
that, on average, a substantial majority of patients
(73%) perform outside the range of healthy control sub-
jects on aggregate NSS measures.21 The average effect
size obtained compares favorably with those reported
for cognition, psychophysiology, frontal-temporal brain
volumes, and regional physiology.24,25,82 The evidence is
complicated by the presence of considerable effect hetero-
geneity, which may reflect the use of difference instru-
ments and patient sample characteristics.83 Hence,
more detailed moderator analysis and more comprehen-
sive reporting practices will become increasingly impor-
tant as the NSS literature expands. Nonetheless, our
preliminary quantification of the NSS effect confirms
the value of this literature in the search for schizophrenia
disease markers and endophenotypes.
Previous studies reported that the frequency of NSS
increased with age in a sample of schizophrenic
patients.84 However, we found that effect sizes based
on summary measures of NSS decreased in magnitude
with increases in the age of patient samples. This relation-
ship may reflect in part the increased frequency of NSS
with age in healthy people.36,84 Thus, higher rates of NSS
in older control samples may have attenuated the effect
found in younger samples. We found an inverse relation-
ship between NSS and age in healthy control samples,
which clearly contradicts this interpretation. On the other
hand, data from patient samples showed a relation be-
tween illness duration and NSS in our study base. This
implies that less chronic, and presumably younger, sam-
ples may include patients with higher rates of neurolog-
ical deficit. The implication is partially supported by
reports of an inverse relationship between age and verbal
memory effect sizes in the neurocognitive literature on
schizophrenia.1 Nonetheless, a similar relationship has
not been found in neuroimaging literatures.82
In terms of chronicity-related moderation of the NSS
effect, we found no statistically significant difference be-
tween first-episode schizophrenia and more chronic
patients. However, we did find an association between
the overall NSS effect and duration of illness. On the
other hand, Chen et al84 previously reported a relation-
ship between NSS and duration of illness that became
nonsignificant when age and education were taken
into account in the analysis. It seems unlikely that
Fig. 6. Funnel Plot for the Meta-analysis of Correlation Between
NSS Total Scores and Symptom Scores in Schizophrenia Patients.
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chronicity is a major factor in amplifying or diminishing
the NSS-schizophrenia association, but the question
should be answerable as the literature expands and pro-
vides a more comprehensive study base for moderator
analysis.
Several studies85,86 have investigated the association
between NSS and gender. While Bjorck et al85 reported
no difference between male and female patients, Duggal
et al86 illustrated that performance in motor sequenc-
ing tasks may be influenced by sex-bound variables.







Healthy Controls P Value
Contrasting NSS total score of schizophrenia
vs controls
Age (y) 30 2069 1573 .008*
Duration of illness 15 867 675 .045*
Education 22 1451 1127 .67
NSS measured by NES or modified NES
Age (y) 20 1151 939 .07
Duration of illness 11 437 356 .02*
Education 14 690 572 .16
Chronic/mixed
Age (y) 23 1687 1255 .05
Duration of illness 10 702 528 .16
Education 17 1286 980 .67
Contrasting NSS-MC score of schizophrenia
vs controls
Age (y) 22 1662 1111 .50
Duration of illness 11 712 543 .86
Education 18 1257 841 .91
NSS measured by NES or modified NES
Age (y) 13 844 503 .65
Duration of illness 8 318 236 .73
Education 10 486 300 .93
Chronic/mixed
Age (y) 17 1265 900 .60
Duration of illness 8 543 407 .65
Education 12 930 597 .92
Contrasting NSS-SI score of schizophrenia
vs controls
Age (y) 21 1575 1057 .16
Duration of illness 12 744 575 .13
Education 17 1170 787 .23
NSS measured by NES or modified NES
Age (y) 14 876 535 .041*
Duration of illness 9 350 268 .21
Education 11 518 332 .54
Chronic/mixed
Age (y) 16 1239 882 .18
Duration of illness 9 647 500 .07
Education 13 1034 690 .56
Contrasting NSS-Mseq (NES) score
of schizophrenia vs controls
Age (y) 14 855 482 .029*
Duration of illness 8 290 193 .57
Education 12 557 354 .15
Chronic/mixed
Age (y) 9 519 307 .037*
Duration of illness 5 193 118 .10
Education 8 421 257 .52
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Unfortunately, we were unable to address gender differ-
ences in our meta-analysis because of inadequate report-
ing of gender composition in the primary studies.
Only 2 studies reported data relevant to the issue of
comorbidity and NSS findings. Sevincok et al87 compared
schizophrenia patients with and without OCD and indi-
cated that OCD-schizophrenia patients had higher scores
than non–OCD-schizophrenia patients on total-NSS. In
terms of substance abuse co-occurring with the illness,
Bersani et al88 compared cannabis-consuming and -non-
consuming schizophrenia patients. The results showed
that NSS were more prevalent in nonconsuming patients.
Unfortunately, no conclusions can be reached with such
limited data. The question of NSS rates in conditions
comorbid with schizophrenia is an important issue that
requires more research attention from investigators.
NSS and Neurocognitive and Symptom Scores
This analysis compiled correlation coefficients between
NSS and neurocognitive and symptom test scores
reported in our primary study base. Cognitive and
NSS data share approximately 10% of their variance,
implying that these data reflect associated, but distinct,
aspects of neurobehavioral function in schizophrenia.
Specific relationships were found between sensory and
motor soft signs and several aspects of cognitive ability
including spatial, executive, and language performance.
However, only SI signs were significantly related to
IQ measures. This suggests that IQ test performance
may require input and coordination of sensory data,
whereas motor system dysfunction associates with dis-
turbances in systems underlying spatial and executive
processing.
The correlations between NSS and clinical symptoms
were relatively modest but significant. The correlation
coefficients between NSS total and total, positive and
negative symptoms scores indicate shared variance
from 2% to 10%, with the weakest relation between
NSS and positive symptom severity. Hence, our results
confirm previous studies demonstrating that NSS are
more prominent in patients with negative symptoms
than in those with positive symptoms.18
Limitations and Future Research
The current study has several limitations. First, the pres-
ence of significant effect variability in some analyses
means that average effect sizes may not represent ade-
quately the underlying populations, which may include
important subsets of patients.83 This is especially nota-
ble in the contrast between patients and controls. Sec-
ond, potential moderators including age and duration
of illness were only coarsely estimated with sample
means. Therefore, the relationships between NSS and
these factors are not clear and require more refined
and detailed analysis. Third, although differences in ef-
fect as a function of NSS instrument (NES vs CNI) were
examined, a comprehensive analysis of scale differences
and score composition was not conducted. Notwith-
standing these limitations, this meta-analysis has
shown, for the first time, that NSS occur in a majority
Table 8. Summary of the Relationships Between Treatment and NSS
Measure Data Results Studies (First Author, Published Year)
Correlation between
NSS and treatment
Reported data Significant King, 199158
Nonsignificant Bartko, 198859; Lane, 199651; Braun, 199546;
Merriam, 199014; Jahn, 200648
No data Significant Liddle, 198760 (included nonsignificant results)
Nonsignificant Liddle, 198760; Cox, 197961; Rossi, 199036;
Schroder, 199262; Cuesta, 199610; Ismail,
199844; Flyckt, 199963; Arango, 200064; Chen,
200065; Biswas, 200766
Contrast medication: low
NSS vs high NSS
Reported data Significant Flashman, 199615
Nonsignificant Das, 200467
No data Significant —
Nonsignificant Bersani, 200468,69; Dazzan, 200469
Contrast NSS low
dose vs high doses
Reported Significant Boks, 200570 (included nonsignificant results)
Nonsignificant Gureje, 198871; Aydemir, 200572; Boks, 200570
No data Nonsignificant Chen, 200573
Contrast NSS baseline
vs posttreated
Reported Nonsignificant Scheffer, 200474; Sevincok, 200675
No data Nonsignificant Emsley, 200576; Mittal, 200777
No data Significant Picchioni, 200678
Nonsignificant Griffich, 199852
Note: NSS, neurological soft signs.
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of the schizophrenia patient population and are similar
to or exceed psychophysiological, cognitive, and neuro-
anatomic findings as indicators or correlates of schizo-
phrenic illness. Reporting limitations in the literature
with respect to key moderators including gender and
chronicity reduce the inferences that can be made about
the generality of these findings. These limitations should
be addressed through improved reporting practices.
In addition, important questions remain concerning
prevalence of specific soft signs in the illness and the
sources of heterogeneity and effect variability in this
population.
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Bachmann S, Bottmer C, Schröder J. Neurological soft signs in
first-episode schizophrenia: a follow-up study. Am J Psychia-
try. 2005;162:2337–2343.
Bersani G, Orlandi V, Gherardelli S, Pancheri P. Cannabis and neu-
rological soft signs in schizophrenia: absence of relationship and
influence on psychopathology. Psychopathology. 2002;35:289–295.
Biswas P, Malhotra S, Malhotra A, Gupta N. Comparative study
of neurological soft signs in schizophrenia with onset in child-
hood, adolescence. Acta Psychiatr Scand. 2007;115:295–303.
Bolton D, Gibb W, Lees A, et al. Neurological soft signs in obses-
sive compulsive disorder: standardized assessment and com-
parison with schizophrenia. Behav Neurol. 1998;11:197–204.
Braun CMJ, Lapierre D. Neurological soft signs in schizophrenia:
are they related to negative or positive symptoms, neuropsy-
chological performance, and violence? Arch Clin Neuropsychol.
1995;10:489–509.
Buchanan RW, Heinrichs DW. The Neurological Evaluation Scale
(NES): a structured instrument for the assessment of neurolog-
ical signs in schizophrenia. Psychiatry Res. 1989;27:335–350.
Chan RCK, Wang L, Chen EE, et al. Neurological soft signs and
their relationships to neurocognitive functions: a re-visit with
the structural equation modeling design. Submitted.
Chan R, Chen E. Executive dysfunctions and neurological manifes-
tations in schizophrenia. Hong Kong J Psychiatry. 2004;14:2–6.
Chan RCK, Wang Y, Ma Z, et al. Neurological soft signs and
neurocognitive deficits along the continuum of schizophrenia
spectrum disorders. Submitted.
Chen EYH, Shapleske J, Luque R, et al. The Cambridge Neuro-
logical Inventory, a clinical instrument for assessment of soft
neurological signs. Psychiatry Res. 1995;56:183–204.
Chen EYH, Lam LCW, Chen RYL, Nguyen DGH. Neurological
signs, age, and illness duration in schizophrenia. J Nerv Ment
Dis. 1996;184:339–345.
Chen EYH, Kwok CL, Au JWY, Chen RYL, Lau BST. Progres-
sive deterioration of soft neurological signs in chronic schizo-
phrenia patients. Acta Psychiatr Scand. 2000;102:342–349.
Chen YLR, Chen YHE, Mak FL. Soft neurological signs in schizo-
phrenic patients and their nonpsychotic siblings. J Nerv Ment
Dis. 2000;188:84–89.
Chen EYH, Chan CK. The Cambridge Neurological Inventory;
clinical, demographic, and ethnic correlates. Psychiatr Ann.
2003;33:202–210.
Chen EYH, Hui CLM, Chan RCK, et al. A 3-year prospective
study of neurological soft signs in first-episode schizophrenia.
Schizophr Res. 2005;75:45–54.
Compton MT, Bollini AM, Mack LM, et al. Neurological soft signs
and minor physical anomalies in patients with schizophrenia and
related disorders, their first degree biological relatives, and non-
psychiatric controls. Schizophr Res. 2007;94:64–73.
Cuesta MJ, Peralta V, de Leon J. Neurological frontal signs and
neuropsychological deficits in schizophrenic patients. Schiz-
ophr Res. 1996;20:15–20.
Cuesta MJ, Peralta V, Zarzuela A, Calvo R, Garcı́a M, Serrano
F. Neurological soft-signs in psychosis: threshold criteria for
discriminating normal controls and for predicting cognitive
impairment. Schizophr Res. 2002;58:263–271.
Dazzan P, Morgan KD, Orr KG, et al. The structural brain cor-
relates of neurological soft signs in AESOP first-episode psy-
choses study. Brain. 2004;127:143–153.
Egan MF, Hyde TM, Bonomo JB, et al. Relative risk of neurolog-
ical signs in siblings of patients with schizophrenia. Am J Psy-
chiatry. 2001;158:1827–1834.
Flashman LA, Flaum M, Gupta S, Andreasen NC. Soft signs and
neuropsychological performance in schizophrenia. Am J Psy-
chiatry. 1996;153:526–532.
Gourion D, Goldberger C, Bourdel MC, et al. Neurological soft-
signs and minor physical anomalies in schizophrenia: differential
transmission within families. Schizophr Res. 2003;63:181–187.
Gourion D, Goldberger C, Olie JP, Lôo H, Krebs MO. Neurological
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